Overview

Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies

Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter study with a phase 1 dose escalation portion and a 2-stage, phase 2 portion, investigating MLN8237 (alisertib) in patients with advanced nonhematological malignancies.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Millennium Pharmaceuticals, Inc.